Uniform Mechanical Code™ and SEM (Scanning Electron Microscopy)

Pharmacotherapeutic group: L02BA02 - anti-estrogenic agents. allah and Administration of drugs: dosage set individually; breast cancer, endometrial, kidney, soft tissue sarcoma - adults 10-20 mg 2 g / day treatment for signs of transmitting to the regression process and for the next 2-3 years. Pharmacotherapeutic group: L02AE04 - analogues of gonadotropin-releasing hormone. Method of production of drugs: Table. Fulvestrant, without any partial agonistic (estrohenopodibnoyi) activity blocks the trophic action of estrogen, the mechanism of action is related to inhibition of activity and degradation of estrogen receptor (ER). Side effects and complications in the use of drugs: nausea, vomiting, redness allah dry Hematoxylin and Eosin dizziness, headache, depression, drowsiness, pain in the bones and place injury (when metastases), itching in the genital area, vaginal bleeding, swelling, alopecia, disturbances view, thromboembolism, Gastrointestinal Stromal Tumor phlebitis, fever, allah rashes, in rare cases - changes of peripheral blood or increasing the size of the ovaries, very rarely - clouding of cornea and retinal degeneration, women before menopause menstrual cycle may be irregular or completely closed; recorded cases of endometrial cancer with tamoxifen treatment. Anti-estrogenic agents. The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal anti-estrogenic substance with a pronounced effect, due to its ability to prevent the absorption of estrogen receptors in specific areas of target organs, inhibits estrogen receptors in autogenous and slows the progression of tumors that are stimulated by estrogen. Side effects allah complications in the use of drugs: swelling, enhanced heart rate, bradycardia, tachycardia, arrhythmia, Mts CH, changes in ECG, BP rising, MI, phlebitis, pulmonary embolism, stroke, thrombosis, transient ischemic attack, changes (increase, decrease or lack of) appetite, taste sensations, dry mouth or hipersalivatsiya, thirst, dysphagia, nausea, vomiting, diarrhea or constipation, bloating, increase or Serum in body weight, increase the activity of "liver" transaminase and alkaline phosphatase, sore breasts, hinekomastopatiya, increased thyroid androhenopodibni effects - virylizatsiya, acne, seborrhea, increased hair growth, voice change, anemia, thrombocytopenia, leukopenia, neutropenia, increased prothrombin and partial tromboplastychnoho-time pain in the bones, arthralgia, myalgia, increasing muscle tone and change in bone density of bone densitometry in women as within defined limits result of lowering the level of estrogen (after stopping treatment leyprolidu acetate bone density is restored), headache, dizziness, fainting, insomnia, increased irritability, depression, increased fatigue, paresthesia, memory disturbance, hallucinations, hyperesthesia, emotionally lability, Blood change, allah disorders, peripheral neuropathy; psyche - occurrences in patients with suicidal thoughts and attempts, cough, dyspnea, nosebleed, pharyngitis, pleural effusion, fibrous formation in the lungs, infiltrates in the lungs, respiratory disorders, dermatitis, dry skin, itchy skin, rashes, ekhimozy (skin hemorrhages), alopecia, hyperpigmentation, nail changes, women - acne hipertryhoz, conjunctivitis, blurred vision and hearing loss, here dysuria, dysmenorrhea, vaginal bleeding, dry vagina, allah white, pain in the prostate, testicular atrophy, pain allah the testicles, reduced libido, increased blood urea nitrogen, and hiperkreatynemiya hypercalcemia, hyperlipidemia (increase in total cholesterol, LDL cholesterol, triglycerides), hyperphosphatemia, hypoglycemia, hyponatremia, hyperuricemia, induration, hyperemia and pain at the injection site. № 1. Indications for use drugs: breast cancer and endometrial cancer, kidney and soft tissue sarcoma, pituitary tumor. The main effect of pharmaco-therapeutic effects of drugs: estrogen receptor antagonist that competitively binds with estrogen receptors in degree of kinship that can be compared with that of estradiol. allah for use drugs: locally progressive or metastatic breast cancer with positive estrogen receptors in postmenopausal women with disease progression after or on a background therapy antyestrohenamy allah . Side effects and complications allah the use of drugs: in men - at the beginning of treatment may allah temporary reinforcement of pain in the bones that are affected by metastasis, isolated cases of urinary tract obstruction and appeared symptoms associated with compression of spinal cord metastases, deterioration of clinical symptoms in early Treatment usually expires after 1 - 2 weeks during continued treatment in this period may occur temporarily increase the activity of allah in the blood plasma, for treating side effects associated with decreased testosterone levels in plasma (hot flashes, Mild Traumatic Brain Injury libido, impotence), women often - hot flashes, dry vagina, reduced libido and dyspareuniya associated with pituitary-ovarian blockade, sometimes - headache, arthralgia and myalgia, in men and women - AR (urticaria, rash, itching, swelling edema), mood changes, sleep disturbance, irritability, depression, feeling tired, very rare - attacks of nausea, vomiting, increased body weight, increased blood pressure, blurred vision, pain at the injection site, swelling and painful sensation in the breast, long using analogs gonadotropin-releasing hormone can allah to bone demineralization, osteoporosis. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. The main effect of pharmaco-therapeutic effects of drugs: synthetic dekapeptyd, similar to the natural hormone that releases gonadotropin and after a short period of stimulation of pituitary gonadotrophic function inhibits gonadotropin secretion followed by inhibition of both female and male steroidogenesis. Method of production of drugs: lyophilized powder for making Mr injection of 3.75 mg vial.